Radial-EBUS: CryoBiopsy Versus Conventional Biopsy: Time-Sample and C-Arm

Kosmıdis, Christoforos; Hohenforst-Schmidt, Wolfgang; Matthaios, Dimitrios; Sapalidis, Konstantinos; Petridis, D.; Perdikouri, Εleni-Isidora; Courcoutsakis, Nikos; Hatzibougias, Dimitris; Arnaoutoglou, Christos; Freitag, Lutz; Ioannidis, Aris; Huang, Haidong; Tolis, Christos; Bai, Chong; Turner, J. Francis

doi:10.3390/ijerph19063569

Cited by 8 publications

(4 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This technique has even higher results when combined with rapid on-site evaluation, and it should always be combined with ROSE. 2 , 4 , 16 , 17 Electromagnetic navigation systems are already on the market in the last 10 years with very high diagnostic results, however; again rapid on-site evaluation should be applied to avoid unnecessary false negative results. 18 , 19 In our study both techniques were efficient with the addition of rapid on-site evaluation, with electromagnetic navigation being faster as a process.…”

Section: Discussionmentioning

confidence: 99%

“…[1] The main tools for lung cancer diagnosis are radial-endobronchial ultrasound, electromagnetic Ivyspring International Publisher navigation, transthoracic biopsy under ultrasound or computed tomography scan. [2][3][4][5][6] Currently we have an additional technique which we use in the diagnostic procedure where we can evaluate our sample firstly if we have cancer cells and secondly if we have enough sample for immunohistochemistry and next generation sequencing (NGS). [7] Early stage lung cancer is usually found with pulmonary nodules on a computed tomography scans (CT).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endobronchial Radiofrequency Ablation for pulmonary nodules with Radial-Ebus and Navigation: Pros and Cons

Hohenforst-Schmidt¹,

Chen²,

Porpodis³

et al. 2023

J. Cancer

Self Cite

View full text Add to dashboard Cite

Introduction: Pulmonary nodules are common in the everyday clinical practice. There is always a diagnostic issue with this imaging finding. Based on the size we can use a variety of imaging and diagnostic techniques. Moreover; in the case of primary lung cancer or metastasis we can use radiofrequency ablation endobronchially. Patients and Methods: We used the radial-endobronchial ultrasound with C-arm and Archemedes, Bronchus electromagnetic navigation in order to acquire biopsy sample and we also used rapid on-site evaluation as a rapid diagnosis for pulmonary nodules. After rapid diagnosis we used the radiofrequency ablation catheter in order to ablate central pulmonary nodules. Results: Both techniques provide efficient navigation, however, with the Bronchus system less time is needed. The new radiofrequency ablation catheter provides efficient results in central lesions with low watts ≤40. Conclusion: We provided in our research a protocol to diagnose and treat such lesions. Future larger studies will provide more data on this subject.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Endobronchial Radiofrequency Ablation for pulmonary nodules with Radial-Ebus and Navigation: Pros and Cons

Hohenforst-Schmidt¹,

Chen²,

Porpodis³

et al. 2023

J. Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…An effort is currently being made by the pneumonology community to inform, educate, and urge people at a high risk of lung cancer to perform computed tomography scans as a method of early lung cancer detection [ 1 ]. We have novel techniques for a safe biopsy in small pulmonary nodules with radial-ebus and electromagnetic navigation systems [ 2 , 3 , 4 , 5 , 6 ]. Unfortunately, the diagnosis of lung cancer is made at an advanced, inoperable stage.…”

Section: Introductionmentioning

confidence: 99%

Non-Small-Cell Lung Cancer Immunotherapy and Sleep Characteristics: The Crossroad for Optimal Survival

et al. 2023

Self Cite

View full text Add to dashboard Cite

Introduction: Non-small-cell lung cancer is still diagnosed at an inoperable stage and systematic treatment is the only option. Immunotherapy is currently considered to be the tip of the arrow as the first-line treatment for patients with a programmed death-ligand 1 ≥ 50. Sleep is known to be an essential part of our everyday life. Patients and Methods: We investigated, upon diagnosis and after nine months, 49 non-small-cell lung cancer patients undergoing immunotherapy treatment with nivolumab and pemprolisumab. A polysomnographic examination was conducted. Moreover, the patients completed the Epworth Sleepiness Scale (ESS), the Pittsburgh Sleep Quality Index (PSQI), the Fatigue Severity Scale (FSS) and the Medical Research Council (MRC) dyspnea scale. Results: Tukey mean-difference plots, summary statistics, and the results of paired t-test of five questionnaire responses in accordance with the PD-L1 test across groups were examined. The results indicated that, upon diagnosis, patients had sleep disturbances which were not associated with brain metastases or their PD-L1 expression status. However, the PD-L1 status and disease control were strongly associated, since a PD-L1 ≥80 improved the disease status within the first 4 months. All data from the sleep questionnaires and polysomnography reports indicated that the majority of patients with a partial response and complete response had their initial sleep disturbances improved. There was no connection between nivolumab or pembrolisumab and sleep disturbances. Conclusion: Upon diagnosis, lung cancer patients have sleep disorders such as anxiety, early morning wakening, late sleep onset, prolonged nocturnal waking periods, daytime sleepiness, and unrefreshing sleep. However, these symptoms tend to improve very quickly for patients with a PD-L1 expression ≥80, because disease status improves also very quickly within the first 4 months of treatment.

show abstract

“…Non-small cell lung cancer is still diagnosed at advanced stage and systemic treatment administration is required. We have nowadays novel tools for the diagnosis and staging of lung cancer like radial-ebus, electromagnetic navigation and convex probe-ebus [ [1] , [2] , [3] , [4] , [5] , [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] ]. However; we still need a successful lung cancer screening program for early lung cancer diagnosis [ 9 ].…”

Section: Introductionmentioning

confidence: 99%